Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Innovative strategies for trial design.

B M Feldman1

  • 1Department of Paediatrics, University of Toronto, Ontario, Canada. brian.feldman@sickkids.on.ca

The Journal of Rheumatology. Supplement
|April 27, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plantar flexion, dorsiflexion, range of movement and hindfoot deviation are important determinants of foot function in children.

Journal of children's orthopaedics·2019
Same author

Measuring activities and participation in persons with haemophilia: A systematic review of commonly used instruments.

Haemophilia : the official journal of the World Federation of Hemophilia·2017
Same author

The outcomes of haemophilia and its treatment: why we need a core set.

Haemophilia : the official journal of the World Federation of Hemophilia·2017
Same author

Comparing the burden of illness of haemophilia between resource-constrained and unconstrained countries: the São Paulo-Toronto Hemophilia Study.

Haemophilia : the official journal of the World Federation of Hemophilia·2017
Same author

Development of CAPTSure<sup>TM</sup> - a new index for the assessment of pediatric postthrombotic syndrome.

Journal of thrombosis and haemostasis : JTH·2016
Same author

Pilot study of once-a-day prophylaxis for youth and young adults with severe haemophilia A.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same journal

GRAPPA 2019 Research Recipient Awards Report.

The Journal of rheumatology. Supplement·2021
Same journal

GRAPPA Treatment Recommendations: An Update From the 2020 GRAPPA Annual Meeting.

The Journal of rheumatology. Supplement·2021
Same journal

GRAPPA Patient Research Partner Network: Update to the GRAPPA 2020 Annual Meeting.

The Journal of rheumatology. Supplement·2021
Same journal

Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group.

The Journal of rheumatology. Supplement·2021
Same journal

GRAPPA 2020 Update From the Education Committee.

The Journal of rheumatology. Supplement·2021
Same journal

The Role of Ultrasound in Research and Clinical Practice in Psoriatic Arthritis: Highlights From the GRAPPA Ultrasound Workshop.

The Journal of rheumatology. Supplement·2021
See all related articles

Pediatric rheumatology trials face low patient numbers. Novel study designs, like the randomized placebo phase design, can improve trial acceptability and patient accrual for rare childhood diseases.

Area of Science:

  • Pediatric Rheumatology
  • Clinical Trial Design
  • Rare Diseases

Background:

  • Childhood rheumatic diseases are rare, limiting subject numbers for clinical trials.
  • Current evidence-based therapeutics for pediatric rheumatology are underdeveloped due to these limitations.
  • Traditional placebo-controlled trials face challenges in acceptability and accrual for these patient populations.

Purpose of the Study:

  • To address the challenges of low subject numbers and trial acceptability in pediatric rheumatology.
  • To propose alternative clinical trial designs that maximize information extraction per subject.
  • To introduce a novel design for evaluating irreversible treatments in rare pediatric diseases.

Main Methods:

  • Discusses the limitations of traditional clinical trial designs in rare diseases.

Related Experiment Videos

  • Explores the benefits of crossover designs for reversible treatments.
  • Proposes the randomized placebo phase design for irreversible treatments.

    • Main Results:

    • Crossover designs increase information yield per subject for reversible treatments.
    • The randomized placebo phase design is presented as a method to enhance acceptability and accrual.
    • This design aims to overcome barriers to evidence-based therapeutic development in pediatric rheumatology.

    Conclusions:

    • Innovative clinical trial designs are crucial for advancing pediatric rheumatology.
    • The randomized placebo phase design offers a promising approach for rare, irreversible conditions.
    • Improving trial design can lead to better therapeutic options for children with rheumatic diseases.